#USA #Carlsbad #Active Motif #Arima Genomics #Hi-C Technology

Active Motif and Arima Genomics Forge Strategic Partnership for 3D Genomics

Active Motif, a recognized leader in the domain of epigenetics and multiomic solutions, has taken a significant step forward in the research landscape by entering into an exclusive global distribution agreement with Arima Genomics. This collaboration aims to enhance the toolkit available for mechanistic, translational, and clinical researchers. With this agreement, Active Motif becomes the sole distributor of Arima's Hi-C products and services, specifically for research applications, while Arima centers its efforts on its Aventa clinical diagnostics platform.

Advancing Genomic Research

The partnership is not just about expanding product availability; it represents a strategic milestone in a sector that is witnessing a burgeoning demand for innovative technologies. The desire for solutions that help researchers comprehend the intricate relationship between genome structure, gene regulation, cellular function, and disease biology is on the rise. As genomic research rapidly evolves past traditional sequence-based analysis, the insights offered by cutting-edge 3D genome mapping technologies—such as Hi-C—are increasingly becoming essential tools in various fields, including cancer research, neuroscience, developmental biology, and precision medicine.

Joe Fernandez, the Chairman and Founder of Active Motif, emphasizes the importance of this agreement: “Researchers are seeking a holistic view of genome functionality. Our collaboration with Arima allows us to provide a more comprehensive array of tools that integrate chromatin accessibility, transcription factor binding, epigenetic regulation, and overall genome architecture.” With the addition of Hi-C technology, Active Motif aims to bolster its already extensive portfolio of genomics and epigenomics tools, significantly enhancing its offering for customers engaged in integrated multiomic research workflows.

Transforming Cancer Diagnostics

On the other hand, this agreement represents a prudent move for Arima Genomics as well. The company is redirecting its focus towards the substantial opportunities presented by its Aventa clinical diagnostics platform, which combines DNA sequence and structural analysis to uncover cancer-driving alterations often missed by conventional diagnostic methods. Tom Willis, Ph.D., the CEO of Arima Genomics, articulates the synergy of this partnership: “By aligning our research-use Hi-C technologies with Active Motif's globally recognized commercial infrastructure and scientific expertise, we are setting the stage for broader access across a variety of research organizations, including academic institutions, pharmaceuticals, biotechnology firms, and clinical research entities.”

Expanding Access to Hi-C Technology

The newly formed agreement is effective immediately, making Arima's Hi-C products and services for research applications available worldwide through Active Motif. The collaboration allows researchers from diverse backgrounds to delve deeper into understanding genomic structure, all the while promoting advancements that could lead to breakthroughs in health and disease management.
This exclusive partnership not only strengthens the capabilities of both companies but also sets a high standard for what integrated multiomics solutions can achieve in transforming our understanding of genetics. As Active Motif continues to innovate in the realm of epigenetics and genomics, its collaboration with Arima Genomics promises to pave the way for unprecedented discoveries in various scientific fields.